Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Phio Pharmaceuticals Corp. (PHIO : NSDQ)

• Company Description    Phio Pharmaceuticals Corp is focused on developing immuno-oncology therapeutics based on its proprietary self-delivering RNAi therapeutic platform. The Company's pipeline consists of RXI-762 and RXI-804 which are in clinical stage. Phio Pharmaceuticals Corp, formerly known as RXi Pharmaceuticals Corporation, is based in Marlborough, United States. Number of Employees: 5

• Price / Volume Information    Yesterday's Closing Price: $2.44 Daily Weekly Monthly 20 Day Moving Average: 183,923 shares Shares Outstanding: 4.80 (millions) Market Capitalization: $11.73 (millions) Beta: 0.91 52 Week High: $5.70 52 Week Low: $0.97 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -1.01% -4.72% 12 Week -10.44% -24.67% Year To Date 35.83% 27.21%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 11 APEX DRIVE SUITE 300A - MARLBOROUGH,MA 01752 USA ph: 508-767-3861 fax: 508-767-3862 ir@phiopharma.com https://phiopharma.com

• General Corporate Information    Officers Robert J. Bitterman - Chief Executive Officer and President Robert Infarinato - Vice President and Chief Financial Officer Patricia Bradford - Director Robert L. Ferrara - Director Curtis A. Lockshin - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 71880W501 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/13/25 Share - Related Items Shares Outstanding: 4.80 Most Recent Split Date: 7.00 (0.11:1) Beta: 0.91 Market Capitalization: $11.73 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.40 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.58 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/13/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.96 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 90.31% vs. Previous Quarter: 51.76% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - -105.65 12/31/24 - -150.16 ROA 06/30/25 - - 03/31/25 - -89.19 12/31/24 - -120.41 Current Ratio 06/30/25 - - 03/31/25 - 10.58 12/31/24 - 5.65 Quick Ratio 06/30/25 - - 03/31/25 - 10.58 12/31/24 - 5.65 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - 2.55 12/31/24 - 0.69 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©